Stage
No active trials
Next date
None yet
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AVTX-009 will be administered as a subcutaneous injection every 4 weeks.”In the company’s words, NCT06603077 on ClinicalTrials.gov
- Tested for
- Hidradenitis Suppurativa
- Main trialPhase 2
- “The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).”In the company’s words, NCT06603077 on ClinicalTrials.gov
Other drugs for Hidradenitis Suppurativa
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 23 Feb 2026 | A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026